RxDoctor Payments Data

David Pazer, MD

Internal Medicine · Ridgefield, CTNPI 1710022264

Payments from drug & device makers

$1,303in general payments, 2019–2025

Across 75 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$184
  • AstraZeneca$167
  • GSK$152
  • Novo Nordisk$147
  • Boehringer Ingelheim$142
  • Amgen$72
  • plus $439 from 11 others

What the payments were for

  • Food & beverage$1,297100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,303 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$208,911
Medicare patients
403
Services billed
4,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$125,905
EliquisApixaban131$103,470
JardianceEmpagliflozin41$59,435
RybelsusSemaglutide14$37,004
JanuviaSitagliptin Phosphate30$33,857
Breo ElliptaFluticasone/Vilanterol42$30,486
MounjaroTirzepatide20$29,837
XareltoRivaroxaban54$29,593
FarxigaDapagliflozin Propanediol15$15,683
EntrestoSacubitril/Valsartan35$15,557
NuedextaDextromethorphan Hbr/Quinidine17$14,703
Budesonide21$8,873
Atorvastatin Calcium527$7,515
Rosuvastatin Calcium389$6,255
SymbicortBudesonide/Formoterol Fumarate12$5,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$147$162,90989 claims
PfizerEliquis$43$103,470131 claims
Boehringer IngelheimJardiance$142$59,43541 claims
GSKBreo Ellipta, Incruse Ellipta, Arexvy$152$37,98965 claims
MerckJanuvia$70$33,85730 claims
Johnson & JohnsonXarelto$52$29,59354 claims
AstraZenecaFarxiga, Symbicort$167$21,47127 claims
NovartisEntresto$43$15,55735 claims
AbbVieSynthroid$184$4,83343 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Ridgefield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →